At the first time point after the initiation of therapy (T1, n = 151), DELFI-TF levels were significantly reduced compared to baseline samples, but still significantly higher than those without cancer (T1 DELFI-TF = 0.45% (95% CI = 0.30–0.63%), p < 0.0001 compared to non-cancer, Wilcoxon rank-sum) (Fig. 2b). This evidence concerns the gene TF and cancer.